New pharmaceuticals are immensely expensive to develop, but that's largely because pharma companies aren't using available data to its full potential.
Its never been easier to start a software business, which is bad for most software companies since it means that they'll have no opportunity to create monopolies.
AI-driven pharma companies are defensible since their work is much more patentable than a typical software-enabled business, and because they'll benefit from data network-effects in the long term.
New pharmaceuticals are immensely expensive to develop, but that's largely because pharma companies aren't using available data to its full potential.
Its never been easier to start a software business, which is bad for most software companies since it means that they'll have no opportunity to create monopolies.
AI-driven pharma companies are defensible since their work is much more patentable than a typical software-enabled business, and because they'll benefit from data network-effects in the long term.